Straits Research is pleased to announce the release of its in-depth report on the global Modified Polypropylene Market, detailing the market's current state, trends, growth drivers, and future opportunities. According to the findings, the global Modified Polypropylene Market was valued at USD XX billion in 2023, and it is projected to reach USD XX billion by 2032, growing at a CAGR of 5.3% during the forecast period from 2024 to 2032. This market report provides an essential overview of the market dynamics, including segmentation, competitive landscape, and opportunities for businesses to capitalize on.
Market Definition:
Modified polypropylene refers to a category of polypropylene that has been chemically or physically altered to enhance its properties, including improved strength, heat resistance, and chemical resistance. These modifications make the material suitable for use in a wide range of industries, including automotive, construction, packaging, medical, and electronics. Modified polypropylene maintains the cost-effectiveness and lightweight nature of traditional polypropylene, while offering superior performance in demanding applications.
The global modified polypropylene market is driven by the increasing demand for lightweight, durable, and cost-efficient materials, particularly in industries such as automotive and packaging. Its ability to withstand high temperatures and resist chemical degradation makes it a preferred choice across diverse industrial applications. The market is also benefitting from the growing trend toward sustainability and the shift towards recyclable materials in various sectors.
Get a Full PDF Sample Copy of the Report @ https://straitsresearch.com/report/modified-polypropylene-market/request-sample
Latest Trends in the Modified Polypropylene Market:
Growth Factors Driving the Modified Polypropylene Market:
Key Market Opportunities in the Modified Polypropylene Market:
Market Segmentation:
The global modified polypropylene market is segmented based on the following categories:
For more detailed information on the market segmentation, access the full report here: https://straitsresearch.com/report/modified-polypropylene-market/segmentation
Key Players in the Modified Polypropylene Market:
The market for modified polypropylene is highly competitive, with several key players dominating the global landscape. Some of the leading companies include:
- LG Chem
- LyondellBasell Industries Holdings B.V.
- SABIC
- Kingfa SCI. & TECH. CO. LTD.
- PetroChina Company Limited
- PolyPacific
- Arkema
- Jiangyin Excen (CGN Advanced Materials Group)
- China XD Plastics Company Limited
- Covestro AG
Market Dominance and Regional Insights:
The Asia Pacific region dominates the global modified polypropylene market, driven by the robust manufacturing base in countries like China, Japan, and South Korea. This region benefits from the high demand for modified polypropylene in automotive, packaging, and construction industries.
The North American region is expected to witness the fastest growth during the forecast period due to the increasing adoption of modified polypropylene in the automotive and packaging sectors, alongside significant investments in technological advancements and sustainable production methods.
Conclusion:
The global modified polypropylene market is experiencing significant growth, driven by the material’s versatile applications in key sectors such as automotive, construction, packaging, and medical industries. With its cost-effectiveness, durability, and increasing demand for sustainable materials, modified polypropylene is well-positioned to meet the evolving needs of various industries. The market offers ample opportunities for growth, and companies can capitalize on emerging trends, technological advancements, and regional expansion to maximize their market presence.
For more information or to purchase the full report, please visit: https://straitsresearch.com/buy-now/modified-polypropylene-market
About Us:
StraitsResearch.com is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & market research reports.
Contact Us:
Email: sales@straitsresearch.comTel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)Website: https://straitsresearch.com/
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.
These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.
Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.
